Latest News

Category: News

See all

Illuccix® Prostate Cancer Imaging Agent Approved in Malta

Clinical, News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MMA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Malta to offer PSMA-PET imaging using a clinically...

Read more

Illuccix® Approved in Norway

ASX, News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by NOMA for the detection and...

Read more

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

ASX, News,

Telix today announces its financial results for the year ended 31 December...

Read more

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Clinical, News,

Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix®...

Read more

Illuccix® Approved in the United Kingdom

ASX, News,

Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix®...

Read more

Illuccix® Approved in Denmark

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish Medicines Agency...

Read more

Telix Full Year Results 2024 Investor Webcast Notification

News,

Telix today advises that it will release its full year results and Australian Annual Report for the period ended 31 December 2024 on Thursday 20 February...

Read more

Statement on impact of U.S. tariffs

News,

Telix currently generates most of its revenue from U.S. sales of Illuccix®. Because of the “just-in-time” nature of radiopharmaceutical products, such products are generally manufactured in close proximity to the...

Read more

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

ASX, News,

Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform,...

Read more

Telix Completes Acquisition of RLS (USA) Inc.

ASX, News,

Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic...

Read more